Antibody treatments may be able to activate the immune system to fight diseases like Parkinson’s, Alzheimer’s and colorectal cancer, but they are less effective when they bind with themselves and other molecules that aren’t markers of disease.
FDA removes hold on three CARsgen CAR-T trials; Ono passes on itolizumab
Plus, news about Kymera Therapeutics, Nanoscope, Eupraxia, Alpha Cognition and EyePoint: FDA’s decision on CARsgen’s CAR-T therapies: The FDA on Thursday Sign up to read
November 2, 2024